News

Amgen Inc (AMGN) reports a 9% revenue increase and advances its diverse portfolio with significant sales growth across key ...
The biotech heavyweight reported adjusted earnings per share of $6.02 for the second quarter, well above the $5.26 anticipated by Wall Street analysts. Revenue climbed 9% from the prior year to $9.18 ...
Amgen Inc. declared a quarterly dividend of $2.38 per share, payable on September 12th to investors of record as of August ...
Explore Amgen's Q2 2025 earnings insights, showcasing 9% revenue growth, robust product performance, and innovation in obesity, rare disease, and ...
Fifteen of the biotechnology company's products delivered at least double-digit sales growth in the second quarter including Repatha, Evenity and Imdelltra. The media giant will take ownership of the ...
Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results , with sales up 9.4% year on year to $9.18 billion. The ...
The stock slipped 3.5% postmarket after the chip maker reported adjusted earnings per share in line with estimates.
Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...
Amgen (NASDAQ:AMGN) surpasses Q2 earnings and revenue expectations with a 9.4% revenue growth. Read more here.
Amgen reported higher profit and revenue in the second quarter after 15 of the biotechnology company's products saw at least double-digit sales growth. The Thousand Oaks, Calif.-based biotechnology ...